IDH1 and cholangiocarcinoma: Additionally, a phase I/II study (NCT05921760) is ongoing to assess the safety, tolerability, and preliminary efficacy of ivosidenib in combination with nivolumab and ipilimumab in previously treated patients with unresectable or metastatic IDH1-mutant CCA [51].